In Vivo Target Engagement Assessment of Nintedanib in a Double-Hit Bleomycin Lung Fibrosis Rat Model
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms27010064 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Vanessa Pitozzi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Chiesi Farmaceutici S.p.A., Global Research and Preclinical Development Area, Largo Belloli, 11/A, 43122 Parma, Italy. Hauptthemen laut MEDLINE: Indoles, Bleomycin, Pulmonary Fibrosis, Protein Kinase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Nintedanib is an anti-fibrotic medication endowed with a multi-kinase inhibitor profile and approved for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Nintedanib is believed to inhibit mainly Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF), and Fibroblast Growth Factor (FGF) receptor kinases. The main objective was to identify potential tissue and/or circulating biomarkers to demonstrate Nintedanib’s target engagement and support its in vivo pharmacodynamic activity, consistent with its proposed mechanism(s) of action. In four independent experiments of bleomycin (BLM)-induced lung fibrosis model in rats, animals received Nintedanib (oral, 100 mg/kg/day) from day 7 post-BLM for 3 weeks. As expected, Nintedanib significantly reduced lung weight, the levels of lung fibrotic markers, and fibrotic areas. Moreover, Nintedanib-treated animals expressed lower levels of FGF2 in lung homogenates and higher plasma and lung levels of VEGF (≥3-fold, p < 0.05) compared to control animals. Lung proteomic analysis revealed the inhibition of receptor tyrosine kinases signaling in Nintedanib-treated animals. Circulating and lung levels of Nintedanib confirmed an optimal tissue distribution in the rat, consistent with the data reported for humans. Although VEGF ligand levels are elevated in the lungs of Nintedanib-treated animals, the VEGF signaling pathway remained functionally downregulated, strongly suggesting compensatory VEGF feedback delivery to its receptor blockade by Nintedanib. In summary, based on the present experimental findings in rats and supporting clinical preliminary evidence, increased VEGF levels can be reasonably considered an indicator of target engagement for Nintedanib and potentially for other VEGF modulators.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chiesi Farmaceutici S.p.A., Global Research and Preclinical Development Area, Largo Belloli, 11/A, 43122 Parma, Italy.
- Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.
- Respiratory Medicine Unit, Department of Medicine & Center for Molecular Medicine, Karolinska Institute, 17176 Stockholm, Sweden.
- Respiratory Disease Unit, Department of Cardiac Thoracic, Vascular Sciences and Public Health, University of Padova, 35128 Padova, Italy.
ORCID-Profile: Maria Gloria Pittelli, Costanza A M Lagrasta, Federico Quaini, Martina Bonatti, Paolo Spagnolo, Marcello Trevisani
Zitieren
APA
Pitozzi, V., Caruso, P. L., Pontis, S., Pioselli, B., Ruscitti, F., Pittelli, M. G., Lagrasta, C. A. M., Quaini, F., Nogara, A. M., Aquino, G., Volta, R., Faietti, M. L., Bonatti, M., Spagnolo, P., & Trevisani, M. (2025). In Vivo Target Engagement Assessment of Nintedanib in a Double-Hit Bleomycin Lung Fibrosis Rat Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27010064
Vancouver
Pitozzi V, Caruso PL, Pontis S, Pioselli B, Ruscitti F, Pittelli MG, et al. In Vivo Target Engagement Assessment of Nintedanib in a Double-Hit Bleomycin Lung Fibrosis Rat Model. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms27010064
BibTeX
@article{Pitozzi2025,
author = {Pitozzi, Vanessa and Caruso, Paola Lorenza and Pontis, Silvia and Pioselli, Barbara and Ruscitti, Francesca and Pittelli, Maria Gloria and Lagrasta, Costanza A M and Quaini, Federico and Nogara, Antonella Maria and Aquino, Giancarlo and Volta, Roberta and Faietti, Maria Laura and Bonatti, Martina and Spagnolo, Paolo and Trevisani, Marcello},
title = {In Vivo Target Engagement Assessment of Nintedanib in a Double-Hit Bleomycin Lung Fibrosis Rat Model},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms27010064}
}
EUVIMED